Inventor
GORDON LESLIE B
US14 patents
⚠️ This page may combine multiple inventors who share the name “GORDON LESLIE B”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
US HEALTH
5 patentsUS8828356B2Sep 9, 2014
Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
US HEALTH6 citations81
US7838531B2Nov 23, 2010
Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
US HEALTH6 citations71
US7297492B2Nov 20, 2007
LMNA gene and its involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and arteriosclerosis
US HEALTH5 citations69
US8034557B2Oct 11, 2011
LMNA gene and its involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and arteriosclerosis
US HEALTH0 citations48
US9115400B2Aug 25, 2015
LMNA gene and its involvement in Hutchinson-Gilford Progeria Syndrome (HGPS) and arteriosclerosis
US HEALTH0 citations45
GORDON LESLIE B
5 patentsUS9381203B2Jul 5, 2016
Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
GORDON LESLIE B4 citations65
US11857541B2Jan 2, 2024
Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
GORDON LESLIE B0 citations55
US8691501B2Apr 8, 2014
Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
GORDON LESLIE B0 citations48
US8257915B2Sep 4, 2012
Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
GORDON LESLIE B0 citations48
US10098871B2Oct 16, 2018
Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
GORDON LESLIE B0 citations44
SAREPTA THERAPEUTICS INC
3 patentsUS10822608B2Nov 3, 2020
Oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC2 citations71
US11802283B2Oct 31, 2023
Oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC0 citations61
US10398721B2Sep 3, 2019
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
SAREPTA THERAPEUTICS INC0 citations50